Skip to main content
CJC-1295 Reviews

An interaction-first review of the CJC-1295 research record — what the human pharmacokinetics actually show, where the DAC and no-DAC stories diverge, and where forum claims outrun the data.

A study citation is worth opening

CJC-1295 references show who was studied and what was measured

A looser waistband can make a fat-loss claim sound easy to believe. The papers below let you check whether researchers measured fat loss or just higher blood readings.

Read the findings in plain wordsCheck the unanswered safety questions

The numbered papers let you check a claim against its study

A better night's rest matters more to you than a scientific-looking claim. A CJC-1295 study can only support the things its researchers actually measured.

Numbers in square brackets point to matching entries in the list below. Each entry gives the paper's authors, date, journal, and a link for reading the study.

Teichman 2006 [1] and Ionescu and Frohman 2006 [3] tested human blood changes. Jette 2005 [2] studied rats and the attached form's longer action.

Other papers tested growth in mice [4] or changes in human blood proteins [5]. Tests of breakdown [7][8] and lab testing and reviews [6][13][14][15] address different questions.

Chemical suppliers disagree on the DAC form's exact makeup and the number used to name that chemical. The number is a label in a chemical catalogue; conflicting labels don't prove what any bottle contains.

You can't settle the chemical's identity from those conflicting supplier descriptions alone. Nor can an animal result or a lab test prove that a shot improves your health.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency (D-Ala2 GHRH analog study). 1994. ↗
  8. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. ↗
  9. Modified GRF (1-29): tetrasubstituted hGRF(1-29) without the DAC albumin-binding moiety; short-acting no-DAC form. Reference overview. ↗
  10. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men (GRF 1-29 pharmacokinetics study). 1986. ↗
  11. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide (ipamorelin PK-PD study). Pharm Res. 1999. ↗
  12. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. ↗
  13. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  14. Advances in the detection of growth hormone releasing hormone synthetic analogs (GHRH-analog detection review). Drug Test Anal. 2021. ↗
  15. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS (immunoaffinity GHRH-MS study). Anal Bioanal Chem. 2016. ↗
  16. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  17. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363(9418):1346-1353 ↗
  18. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  19. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  20. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  21. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  22. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗